León GG, Morfín OR, Petersen MS, Pérez GHR, González DE, Rodríguez NE

Language: Spanish
References: 29
Page: 66-69
PDF size: 61.71 Kb.

ABSTRACT

Brucellosis is a frequent zoonotic infection of humans in Mexico. This disease occurs commonly in the northern states of Coahuila, Nuevo Leon, Sonora, and Chihuahua, where the disease in cattle, sheep, and goats is not eradicated.
The sporadic human cases of brucellosis seen outside of the endemic areas represent a diagnostic challenge due to its diverse, nonspecific clinical manifestations. In chronic human brucellosis, osteoarticular involvement and ocular brucellosis are frequent organ systems affected.
In absence of positive blood or bone marrow cultures, the diagnosis of brucellosis is made with the help of positive serologic tests.
The appropriate treatment of chronic human brucellosis involves the use of combination therapy administered for prolonged periods in order to prevent relapses.

REFERENCES

1. Pappas G, Akritidis N, Bosilkovski M, Tsianos E. “Brucellosis”. N Engl J Med 2005; 352(22): 2325-2336.

2. Franco MP, Mulder M, Gilman RH, Smits HL. “Human brucellosis”. Lancet Infect Dis 2007; 7(12): 775-786.

3. Luna-Martinez JE, Mejia-Teran C. “Brucellosis in Mexico: Current status and trends”. Vet Microbiol 2002; 90(1-4): 19-30.

4. Lucero NE, Ayala SM, Escobar GI, Jacob NR. “Brucella isolated in humans and animals in Latin America from 1968 to 2006”. Epidemiol Infect 2008; 136(4): 496-503.

5. Corbel MJ. “Brucellosis: An overview”. Emerg Infect Dis 1997; 3(2): 213-221.

6. Pappas G, Papadimitriou P, Akritidis N, Christou L, Tsianos EV. “The new global map of human brucellosis”. Lancet Infect Dis 2006; 6(2): 91-99.

7. Ko J, Splitter GA. “Molecular host-pathogen interaction in brucellosis: Current understanding and future approaches to vaccine development for mice and humans”. Clin Microbiol Rev 2003; 16(1): 65-78.

8. Doyle TJ, Bryan RT. “Infectious disease morbidity in the US region bordering Mexico, 1990-1998”. J Infect Dis 2000; 182(5): 1503-1510.

9. Troy SB, Rickman LS, Davis CE. “Brucellosis in San Diego: Epidemiology and species-related differences in acute clinical presentations”. Medicine (Baltimore) 2005; 84(3): 174-187.

10. Lopez-Merino A, Migranas-Ortiz R, Perez-Miravete A et al. “Seroepidemiology of brucellosis in Mexico”. Salud Pública Méx 1992; 34(2): 230-240.

11. Lopez-Moreno HS, Fonseca-Najar JM, Osuna-Ramirez I, Rendon-Maldonado JG, Uribe-Beltran M de J, Hernandez- Ramirez CV. “Detection of human brucellosis in patients from Sinaloa, Mexico, in 2006”. Salud Pública Méx 2008; 50(4): 274-275.

12. Torres-Padilla JC, Lopez-Merino A, Garcia-Escamilla RM, Gutierrez-Garcia JN. “Anti-brucella antibody seroprevalence in blood donors for therapeutic ends at three blood banks of the Mexican Institute of Social Security”. Gac Med Mex 2004; 140(4): 391-398.

13. Solorio-Rivera JL, Segura-Correa JC, Sanchez-Gil LG. “Seroprevalence of and risk factors for brucellosis of goats in herds of Michoacan, Mexico”. Prev Vet Med 2007; 82(3-4): 282-290.

14. Mikolon AB, Gardner IA, Hernandez De Anda J, Hietala SK. “Risk factors for brucellosis seropositivity of goat herds in the Mexicali Valley of Baja California, Mexico”. Prev Vet Med 1998; 37(1-4): 185-195.

15. Vrioni G, Pappas G, Priavali E, Gartzonika C, Levidiotou S. “An eternal microbe: Brucella DNA load persists for years after clinical cure”. Clin Infect Dis 2008; 46(12): e131-e136.

16. Buzgan T, Karahocagil MK, Irmak H et al. “Clinical manifestations and complications in 1028 cases of brucellosis: A retrospective evaluation and review of the literature”. Int J Infect Dis 2009; 14(3): e257-e258.

17. Rolando I, Olarte L, Vilchez G et al. “Ocular manifestations associated with brucellosis: A 26-year experience in Peru”. Clin Infect Dis 2008; 46(9): 1338-1345.

18. Sungur GK, Hazirolan D, Gurbuz Y, Unlu N, Duran S, Duman S. “Ocular involvement in brucellosis”. Can J Ophthalmol 2009; 44(5): 598-601.

19. Roushan MR, Amiri MJ, Laly A, Mostafazadeh A, Bijani A. “Follow-up standard agglutination and 2-mercaptoethanol tests in 175 clinically cured cases of human brucellosis”. Int J Infect Dis 2009; 14(3): e250-e253.

20. Mert A, Ozaras R, Tabak F et al. “The sensitivity and specificity of Brucella agglutination tests”. Diagn Microbiol Infect Dis 2003; 46(4): 241-243.

21. Young EJ. “Serologic diagnosis of human brucellosis: Analysis of 214 cases by agglutination tests and review of the literature”. Rev Infect Dis 1991; 13(3): 359-372.

22. Gomez MC, Nieto JA, Rosa C et al. “Evaluation of seven tests for diagnosis of human brucellosis in an area where the disease is endemic”. Clin Vaccine Immunol 2008; 15(6): 1031-1033.

23. Mitka S, Anetakis C, Souliou E, Diza E, Kansouzidou A. “Evaluation of different PCR assays for early detection of acute and relapsing brucellosis in humans in comparison with conventional methods”. J Clin Microbiol 2007; 45(4): 1211-1218.

24. Rolando I, Vilchez G, Olarte L et al. Brucellar uveitis: Intraocular fluids and biopsy studies”. Int J Infect Dis 2009; 13(5): e206-e211.

25. Skalsky K, Yahav D, Bishara J, Pitlik S, Leibovici L, Paul M. “Treatment of human brucellosis: Systematic review and meta-analysis of randomised controlled trials”. BMJ 2008; 336(7646): 701-704.

26. Falagas ME, Bliziotis IA. “Quinolones for treatment of human brucellosis: Critical review of the evidence from microbiological and clinical studies”. Antimicrob Agents Chemother 2006; 50(1): 22-33.

27. Solera J, Geijo P, Largo J et al. “A randomized, doubleblind study to assess the optimal duration of doxycycline treatment for human brucellosis”. Clin Infect Dis 2004; 39(12): 1776-1782.

28. Ariza J, Bosilkovski M, Cascio A et al. “Perspectives for the treatment of brucellosis in the 21st century: The Ioannina recommendations”. PLoS Med 2007; 4(12): e317.

29. Lopez-Merino A, Contreras-Rodriguez A, Migranas-Ortiz R et al. “Susceptibility of Mexican brucella isolates to moxifloxacin, ciprofloxacin and other antimicrobials used in the treatment of human brucellosis”. Scand J Infect Dis 2004; 36(9): 636-638.